Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Jun 2023 Final results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 07 Mar 2023 Planned End Date changed from 20 Jul 2023 to 20 Sep 2024.